Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow.
Recombinant human interleukin-6 (IL-6) causes both a thrombocytosis and leukocytosis. The thrombocytosis is caused by an accelerating thrombocytopoiesis, but the mechanism of the leukocytosis is unknown. This study was designed to determine the relative contributions of marrow stimulation and intravascular demargination to the IL-6 induced neutrophilia. IL-6 (2 microgram/kg), administered intravenously to rabbits, caused a biphasic neutrophilia with an initial peak at 3 h and a second peak at 9 h. Using the thymidine analog 5'-bromo-2'-deoxyuridine (BrdU) to label dividing polymorphonuclear leukocytes (PMNs) in the bone marrow, we showed that IL-6 treatment mobilizes PMNs from the marginated pool into the circulating pool at 2-6 h with a decrease in L-selectin expression on PMNs and also accelerates the release of PMNs from the postmitotic pool in the bone marrow at 12-24 h. We have concluded that IL-6 causes a biphasic neutrophilia wherein the first peak results from the mobilization of PMNs into the circulating pool from the marginated pool and the second peak results from an accelerated bone marrow release of PMNs.
Suwa
T
T
Pulmonary Research Laboratory, University of British Columbia, St. Paul's Hospital, Vancouver, British Columbia, Canada V6Z 1Y6.
Hogg
J C
JC
English
D
D
Van Eeden
S F
SF
D000818:Animals; D000963:Antimetabolites; D001853:Bone Marrow / Q000276:immunology*; D001854:Bone Marrow Cells / Q000187:drug effects; D001973:Bromodeoxyuridine; D018821:CD18 Antigens / Q000032:analysis; D002454:Cell Differentiation / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D015850:Interleukin-6 / Q000494:pharmacology*; D019041:L-Selectin / Q000032:analysis; D009504:Neutrophils / Q000737:chemistry / Q000166:cytology* / Q000187:drug effects*; D011817:Rabbits
D000963:Antimetabolites; D018821:CD18 Antigens; D015850:Interleukin-6; D019041:L-Selectin; D001973:Bromodeoxyuridine